ASCL1 Drives Tolerance to Osimertinib in EGFR Mutant Lung Cancer in Permissive Cellular Contexts.
Bomiao HuMarc WiesehöferFernando J de MiguelZongzhi Z LiuLok Hei ChanJungmin ChoiMary Ann MelnickAnna Arnal-EstapeZenta WaltherDejian ZhaoFrancesc LopezAnna WurtzGuoping CaiRong FanScott N GettingerAndrew Z XiaoQin YanRobert J HomerDon X NguyenKaterina PolitiPublished in: Cancer research (2024)
Analysis of residual disease following tyrosine kinase inhibitor treatment identified heterogeneous and context-specific mechanisms of drug tolerance in lung cancer that could lead to the development of strategies to forestall drug resistance. See related commentary by Rumde and Burns, p. 1188.